Literature DB >> 19281881

How we say no: norepinephrine, inferior frontal gyrus, and response inhibition.

Gary Aston-Jones1, Joshua I Gold.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19281881      PMCID： PMC2777813          DOI： 10.1016/j.biopsych.2009.01.022

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  11 in total

1.  Phasic activation of monkey locus ceruleus neurons by simple decisions in a forced-choice task.

Authors:  Edwin C Clayton; Janusz Rajkowski; Jonathan D Cohen; Gary Aston-Jones
Journal:  J Neurosci       Date:  2004-11-03       Impact factor: 6.167

Review 2.  An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance.

Authors:  Gary Aston-Jones; Jonathan D Cohen
Journal:  Annu Rev Neurosci       Date:  2005       Impact factor: 12.449

Review 3.  Adrenergic pharmacology and cognition: focus on the prefrontal cortex.

Authors:  Brian P Ramos; Amy F T Arnsten
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

4.  Role of frontal eye fields in countermanding saccades: visual, movement, and fixation activity.

Authors:  D P Hanes; W F Patterson; J D Schall
Journal:  J Neurophysiol       Date:  1998-02       Impact factor: 2.714

Review 5.  Molecular genetics of attention-deficit/hyperactivity disorder.

Authors:  Stephen V Faraone; Roy H Perlis; Alysa E Doyle; Jordan W Smoller; Jennifer J Goralnick; Meredith A Holmgren; Pamela Sklar
Journal:  Biol Psychiatry       Date:  2005-01-21       Impact factor: 13.382

6.  Low-dose methylphenidate actions on tonic and phasic locus coeruleus discharge.

Authors:  David M Devilbiss; Craig W Berridge
Journal:  J Pharmacol Exp Ther       Date:  2006-09-15       Impact factor: 4.030

Review 7.  New potential leads in the biology and treatment of attention deficit-hyperactivity disorder.

Authors:  B J Casey; Joel T Nigg; Sarah Durston
Journal:  Curr Opin Neurol       Date:  2007-04       Impact factor: 5.710

Review 8.  The cognitive neuroscience of response inhibition: relevance for genetic research in attention-deficit/hyperactivity disorder.

Authors:  Adam R Aron; Russell A Poldrack
Journal:  Biol Psychiatry       Date:  2004-12-23       Impact factor: 13.382

9.  Modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI.

Authors:  Michael J Minzenberg; Andrew J Watrous; Jong H Yoon; Stefan Ursu; Cameron S Carter
Journal:  Science       Date:  2008-12-12       Impact factor: 47.728

Review 10.  Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update.

Authors:  Jefferson Prince
Journal:  J Clin Psychopharmacol       Date:  2008-06       Impact factor: 3.153
View more
  10 in total

Review 1.  Cognitive enhancement as a treatment for drug addictions.

Authors:  Mehmet Sofuoglu; Elise E DeVito; Andrew J Waters; Kathleen M Carroll
Journal:  Neuropharmacology       Date:  2012-06-23       Impact factor: 5.250

2.  Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals.

Authors:  Helen Fox; Mehmet Sofuoglu; Rajita Sinha
Journal:  J Psychopharmacol       Date:  2015-01-07       Impact factor: 4.153

3.  Haplotype polymorphism in the alpha-2B-adrenergic receptor gene influences response inhibition in a large Chinese sample.

Authors:  Xuemei Lei; Chuansheng Chen; Qinghua He; Robert Moyzis; Gui Xue; Chunhui Chen; Zhongyu Cao; Jin Li; He Li; Bi Zhu; Mingxia Zhang; Jun Li; Qi Dong
Journal:  Neuropsychopharmacology       Date:  2012-01-04       Impact factor: 7.853

4.  Phasic and tonic patterns of locus coeruleus output differentially modulate sensory network function in the awake rat.

Authors:  David M Devilbiss; Barry D Waterhouse
Journal:  J Neurophysiol       Date:  2010-10-27       Impact factor: 2.714

Review 5.  Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders.

Authors:  Cameron S Carter; Deanna M Barch; Edward Bullmore; James Breiling; Robert W Buchanan; Pamela Butler; Jonathan D Cohen; Mark Geyer; Randy Gollub; Michael F Green; Judith Jaeger; John H Krystal; Holly Moore; Keith Nuechterlein; Trevor Robbins; Steven Silverstein; Edward E Smith; Milton Strauss; Til Wykes
Journal:  Biol Psychiatry       Date:  2011-05-06       Impact factor: 13.382

Review 6.  The clinical neurobiology of drug craving.

Authors:  Rajita Sinha
Journal:  Curr Opin Neurobiol       Date:  2013-06-10       Impact factor: 6.627

7.  The involvement of noradrenaline in rapid eye movement sleep mentation.

Authors:  Claude Gottesmann
Journal:  Front Neurol       Date:  2011-12-12       Impact factor: 4.003

8.  Response inhibition and cognitive appraisal in clients with acute stress disorder and posttraumatic stress disorder.

Authors:  Abass Abolghasemi; Fereshteh Bakhshian; Mohammad Narimani
Journal:  Iran J Psychiatry       Date:  2013-08

Review 9.  Neuromodulator and Emotion Biomarker for Stress Induced Mental Disorders.

Authors:  Simeng Gu; Wei Wang; Fushun Wang; Jason H Huang
Journal:  Neural Plast       Date:  2016-03-14       Impact factor: 3.599

10.  Atypical response inhibition and error processing in 22q11.2 Deletion Syndrome and schizophrenia: Towards neuromarkers of disease progression and risk.

Authors:  Ana A Francisco; Douwe J Horsthuis; Maryann Popiel; John J Foxe; Sophie Molholm
Journal:  Neuroimage Clin       Date:  2020-07-17       Impact factor: 4.881
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.